

**QCDR Measure:**

AAO-10: Exudative Age-Related Macular Degeneration: Loss of Visual Acuity

National Quality Strategy Domain:

Effective Clinical Care

Measure Type:

Outcome

Description:

Percentage of patients with a diagnosis of exudative age-related macular degeneration, being treated with anti-VEGF agents, with of loss of less than 0.3 logMar of visual acuity within the past 12 months.

Instructions:

This measure is to be reported a minimum of once per reporting period for patients seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with exudative age-related macular degeneration (in either one or both eyes) will submit this measure.

Denominator:

All patients aged 18 years or older with a diagnosis of exudative age-related macular degeneration and documentation of laterality (OD, OS, OU)

Denominator Criteria

Patients aged ≥ 18 years

AND

Diagnosis of Exudative Age-Related Macular Degeneration

- Exudative age-related macular degeneration (ICD-10: H35.32)

AND

Four or more recorded visual acuity values in the past 12 months

AND

Treatment with Anti-VEGF Agents

- Bevacizumab (Avastin®) injections (CPT: 67028 & HCPCS: J9035; CPT: 67028 & HCPCS: J3490; CPT: 67028 & HCPCS: J3590; CPT: 67028 & HCPCS: C9257)
- Ranibizumab (Lucentis®) injections (CPT: 67028 & HCPCS: J2778)

- Aflibercept (EYLEA®) injections (CPT: 67028 & HCPCS: J0178)

Numerator:

Patients with four or more recorded visual acuity values within the past 12 months; loss of visual acuity less than 0.3 logMar. Visual acuity of the eye(s) being treated will be evaluated.

Numerator Options:

Performance Met:	Patients who achieved a loss in visual acuity of ≤ 0.3 logMar
Performance Not Met:	Patients who did not achieve a loss in visual acuity of ≤ 0.3 logMar

Improvement Notation:

Higher score indicates better performance